Inderal La

Thyroid Crisis, Atrial Fibrillation, Migraine + 23 more

Treatment

5 FDA approvals

20 Active Studies for Inderal La

What is Inderal La

Propranolol

The Generic name of this drug

Treatment Summary

Propranolol is a medication used to treat high blood pressure. It is a combination of two enantiomers, with the S(-)-enantiomer having 100 times the binding affinity for beta adrenergic receptors. Propranolol has been approved by the FDA since 1967 and is used to treat a number of other conditions.

Inderal

is the brand name

image of different drug pills on a surface

Inderal La Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Inderal

Propranolol

1967

471

Approved as Treatment by the FDA

Propranolol, also known as Inderal, is approved by the FDA for 5 uses including Obstructive Hypertrophic Cardiomyopathy and Tremor, Essential .

Obstructive Hypertrophic Cardiomyopathy

Tremor, Essential

Helps manage Tremor, Essential

Essential Tremor

Helps manage Tremor, Essential

Cardiomyopathy, Hypertrophic

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Hydrochlorothiazide

Effectiveness

How Inderal La Affects Patients

Propranolol is a drug used to treat high blood pressure. It can be taken in one or two doses each day and its effects last long. If someone stops taking propranolol suddenly, they may experience chest pain or heart attacks.

How Inderal La works in the body

Propranolol blocks certain receptors in the body, resulting in decreased blood vessel growth and increased cell death. It also reduces the levels of hormones that regulate blood pressure.

When to interrupt dosage

The measure of Inderal La is contingent upon the identified affliction, including Catecholamines, Hypertensive illness and Hemangiomas. The amount of dosage is contingent upon the method of delivery (e.g. Solution - Oral or Capsule, extended release - Oral) as specified in the table below.

Condition

Dosage

Administration

Adrenergic Alpha-Antagonists

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Heart Attack

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Tachyarrhythmia caused by Digitalis intoxication

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Psychomotor Agitation

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Tremor

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Thyrotoxicosis

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Chest Pain

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Supraventricular Arrhythmias

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Hemangioma

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Cardiomyopathy, Hypertrophic

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Proliferating Infantile Hemangioma

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Hypertensive disease

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Performance Anxiety

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Pheochromocytoma

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Ventricular Tachycardia

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Migraine

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Gastroesophageal variceal hemorrhage prophylaxis

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Catecholamines

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Migraine Disorders

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Atrial Fibrillation

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Warnings

Inderal La has fifteen contraindications and should not be adopted when confronting the conditions presented in the following table.

Inderal La Contraindications

Condition

Risk Level

Notes

Heart Decompensation

Do Not Combine

Bronchial Spasm

Do Not Combine

Asthma

Do Not Combine

Infants Weighing <2kg

Do Not Combine

Low Blood Pressure

Do Not Combine

Sick Sinus Syndrome

Do Not Combine

Asthma

Do Not Combine

Pheochromocytoma

Do Not Combine

Atrioventricular Block

Do Not Combine

Slow Heart Rate

Do Not Combine

Shock, Cardiogenic

Do Not Combine

Heart Decompensation

Do Not Combine

Prematurity

Do Not Combine

Sinus Bradycardia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Propranolol may interact with Pulse Frequency

There are 20 known major drug interactions with Inderal La.

Common Inderal La Drug Interactions

Drug Name

Risk Level

Description

4-Bromo-2,5-dimethoxyphenethylamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Propranolol.

4-Methoxyamphetamine

Major

The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Propranolol.

Abediterol

Major

Propranolol may decrease the bronchodilatory activities of Abediterol.

Adrafinil

Major

The therapeutic efficacy of Adrafinil can be decreased when used in combination with Propranolol.

Agrostis gigantea pollen

Major

The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Propranolol.

Inderal La Toxicity & Overdose Risk

Signs of an overdose of propranolol include low blood pressure, seizures due to low blood sugar, restlessness, and difficulty sleeping. People with asthma may have difficulty breathing. To treat an overdose, medical professionals will monitor vital signs and mental status, and administer fluids to raise blood pressure, atropine to slow an irregular heartbeat, and drugs to open up the airways. If the patient does not respond to fluids, they may be given glucagon followed by drugs that increase the activity of certain hormones. Dialysis usually cannot remove propranolol from the body because it binds strongly to proteins.

image of a doctor in a lab doing drug, clinical research

Inderal La Novel Uses: Which Conditions Have a Clinical Trial Featuring Inderal La?

249 active studies are currently assessing the potential of Inderal La in providing relief from Migraine, Catecholamine-induced disorders and Hypertensive diseases.

Condition

Clinical Trials

Trial Phases

Atrial Fibrillation

94 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Heart Attack

23 Actively Recruiting

Not Applicable, Phase 1, Phase 4, Phase 2, Early Phase 1, Phase 3

Coronary Artery Disease

1 Actively Recruiting

Not Applicable

Chest Pain

2 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Adrenergic Alpha-Antagonists

0 Actively Recruiting

Migraine

51 Actively Recruiting

Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1

Hemangioma

0 Actively Recruiting

Gastroesophageal variceal hemorrhage prophylaxis

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Catecholamines

0 Actively Recruiting

Thyroid Crisis

0 Actively Recruiting

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Pheochromocytoma

0 Actively Recruiting

Thyrotoxicosis

0 Actively Recruiting

Cardiovascular Mortality

0 Actively Recruiting

Myocardial Infarction

0 Actively Recruiting

Tremor

0 Actively Recruiting

Cardiomyopathy, Hypertrophic

0 Actively Recruiting

Proliferating Infantile Hemangioma

0 Actively Recruiting

Psychomotor Agitation

0 Actively Recruiting

Inderal La Reviews: What are patients saying about Inderal La?

5

Patient Review

8/26/2013

Inderal La for Essential Tremor

I've been using Inderal LA for over two decades to manage a head tremor. It's been incredibly effective, but can sometimes be tough to coordinate with my asthma medication.

5

Patient Review

10/7/2014

Inderal La for Migraine Prevention

This medication has been great for me. I used to get two migraines a month, but since starting this treatment, I haven't had any at all.

4.7

Patient Review

10/19/2009

Inderal La for Migraine Prevention

I was prescribed this medication about 9 years ago for a rapid heartbeat. It worked for several years then had to increase the dose because symptoms returned. Unfortunately, I also experienced EXTREME HAIR LOSS - which is apparently a common side effect of beta blockers (according to my research).

4.7

Patient Review

5/15/2011

Inderal La for Migraine Prevention

Since starting this medication a few weeks ago, my migraines have greatly improved. Although I do feel tired the day after taking it.

4.7

Patient Review

3/16/2010

Inderal La for High Blood Pressure

This treatment is great! It really helped me and I'm grateful for it.

4.7

Patient Review

9/27/2009

Inderal La for Migraine Prevention

4.3

Patient Review

7/22/2015

Inderal La for Migraine Prevention

The drug has been helpful in managing my migraines, though I haven't seen a total prevention of them. The most difficult side effect is an uncontrollable hunger; however, I've found that drinking water and chewing gum helps to alleviate this issue somewhat.

4.3

Patient Review

8/3/2013

Inderal La for Ventricular Rate Control in Atrial Fibrillation

This medication caused an irregular heart beat for me.

4

Patient Review

4/30/2011

Inderal La for Essential Tremor

I've been using these Inderal tablets for over 15 years to help with my hand tremor. They work well, but I have noticed that if I take them too regularly, they become less effective. I haven't increased the 40mg dose per day because I read on this site that it shouldn't be taken by patients with low blood sugar (which is my case). If anyone could provide clarification on this from a medical standpoint, I would appreciate it.

4

Patient Review

11/21/2011

Inderal La for High Blood Pressure

This medication was easy to take and had minimal side effects. My blood pressure lowered significantly, and it also took care of my minor tremors.

3.7

Patient Review

1/28/2014

Inderal La for Migraine Prevention

Though this drug is very effective in preventing migraines, the constant tiredness it causes is difficult to manage. I also have trouble working out; if I take the medication before going to the gym, I become nauseous, sweaty and dizzy. Because of these side effects, I stopped taking the drug a couple years ago. However, since my migraines have returned (I average 5 per month), I am reconsidering. Taking magnesium/B2 for several months does not seem to be an effective alternative to prescription drugs.

3

Patient Review

3/15/2010

Inderal La for Osteoporosis

I was recently prescribed Inderal LA 60 mg to take once a day for tremors in my hands that may be caused by taking Zoloft. I have been on the medication for about a month now and I still have shaky hands. I am seeing my doctor soon to find out what is going on, but as of right now, it does not seem like this drug is effective for treating tremors. Has anyone else had a similar experience using this drug?

2.3

Patient Review

7/7/2012

Inderal La for Essential Tremor

The tremors have not gone away and they are still affecting my daily life.

1.3

Patient Review

11/4/2011

Inderal La for High Blood Pressure

I experienced some serious side effects after taking this drug for a few years. My blood pressure went down, but I developed impotence and insomnia that didn't go away even after I stopped taking the drug. In 2009, I also developed Peyronie's disease. It's worrying that all of these conditions are rare side effects of this medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about inderal la

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Inderal LA treat?

"INDICATIONS:

Propranolol HCl is indicated for the treatment of high blood pressure, angina pectoris, and hypertrophic subaortic stenosis. It is also indicated for the prevention of migraine headaches."

Answered by AI

Is propranolol ER the same as Inderal LA?

"HCL

Propanolol HCL ER is used to lower blood pressure and heart rate, making it easier for the heart to pump blood to the rest of the body. It can also be used to prevent migraine headaches. Propanolol HCL ER works by relaxing the blood vessels in the brain that cause migraines."

Answered by AI

What is difference between Inderal and Inderal LA?

"There was no significant difference in blood pressure levels between conventional propranolol and 'Inderal' LA, but the mean peak blood level of propranolol was lower with 'Inderal' LA and occurred later."

Answered by AI

What is Inderal LA 60 mg used for?

"This medication is a beta blocker that is used to treat high blood pressure, irregular heartbeats, shaking (tremors), and other conditions as determined by your doctor. It is used after a heart attack to improve survival rates. It is also effective in preventing migraine headaches and chest pain (angina)."

Answered by AI

Clinical Trials for Inderal La

Image of University of Texas Medical Branch in Galveston, United States.

Middle Meningeal Artery Stimulation for Migraine

18 - 100
All Sexes
Galveston, TX

This study is testing a new way to help with migraine headaches. Researchers want to see if it's safe and doable to stimulate a blood vessel in the head (called the middle meningeal artery) with microcatheters and microwires. This has never been done before for migraines and is an investigational treatment that is not part of standard migraine treatment. This stimulation would happen just before giving the standard lidocaine treatment, which is already routinely used for migraines. The goal is to see whether this new step could help improve headache outcomes. Two FDA-cleared medical devices will be used, the Cadwell Cascade 32 PRO and the Cadwell Guardian IONM System, to perform the stimulation and monitoring. In this study, the Cascade 32 PRO will be used in a way that is not part of its usual approved purpose (this is called "off-label" use) to gently deliver electrical pulses through a microcatheter. The Cadwell Guardian IONM System will be used in its normal, FDAapproved way for continuous monitoring during stimulation.

Recruiting
Has No Placebo

University of Texas Medical Branch

Peter Kan, MD,MPH

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Have you considered Inderal La clinical trials?

We made a collection of clinical trials featuring Inderal La, we think they might fit your search criteria.
Go to Trials
Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Northwestern University in Chicago, United States.

Exercise Program for Atrial Fibrillation and Heart Failure

60 - 99
All Sexes
Chicago, IL

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are very common conditions that often occur together and result in worsening symptoms and reduced quality of life (QoL). Limitations being able to participate in activities of daily living is a primary complaint for AF-HFpEF patients, yet effective strategies to address this issue remain limited. While exercise interventions targeting aerobic training (AT) are recommended for patients with AF and HFpEF, unique challenges exist in this patient population who tend to be older. Specifically, many older patients with AF and HFpEF have muscle weakness, sarcopenia and frailty, that can make aerobic-focused exercise difficult and less tolerable. This study proposes that starting with progressive resistance training (PRT) before aerobic exercise may overcome these issues by improving muscle strength, making AT more manageable, and leading to better health outcomes. The goal of this study is to assess whether a sequential exercise program, named 'PREACTIVE' improves how people feel, decrease the amount of symptoms, and their ability to participate in exercise and activities. This study will specifically test a sequenced exercise approach of resistance training followed by aerobic exercise to improve symptoms, and quality of life in AF-HFpEF.

Waitlist Available
Has No Placebo

Northwestern University

Deepika Laddu, PhD

Image of Fort Bend ISD in Sugar Land, United States.

Wellbeing Interventions for Anxiety

10 - 20
All Sexes
Sugar Land, TX

The goal of this clinical trial is to learn if psychology and music based interventions can impact anxiety and overall wellbeing in adolescents enrolled in choral music classes. The main questions it aims to answer are: Do specific psychology and music based breathing interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based performance anxiety reduction interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based emotion regulation interventions impact anxiety and overall wellbeing in adolescents? Researchers will compare results of pre-test data, post-test data, qualitative interviews, and surveys of adult choral directors to see if there is a measurable impact on adolescent anxiety and overall wellbeing. Participants will: * Use box breathing during choral music warm-ups to connect choral breathing to breathing for anxiety reduction * Use "magnify" technique to compare cognitive distortions regarding an upcoming performance that may cause anxiety to the most likely realistic outcome * Use emotion regulation through song lyrics technique to connect lyrics of choral music repertoire to participants experienced emotions

Waitlist Available
Has No Placebo

Fort Bend ISD

Jane Kuehne, PhD

Have you considered Inderal La clinical trials?

We made a collection of clinical trials featuring Inderal La, we think they might fit your search criteria.
Go to Trials
Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA

The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.

Phase 4
Waitlist Available

Inova Alexandria Hospital

Have you considered Inderal La clinical trials?

We made a collection of clinical trials featuring Inderal La, we think they might fit your search criteria.
Go to Trials